Baird raised the firm’s price target on Dianthus (DNTH) to $67 from $50 and keeps an Outperform rating on the shares. The firm said they are positive on the company’s Phase 2 MaGic data profile in gMG supporting a differentiated profile.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DNTH:
- Closing Bell Movers: Nebius up over 40% on Microsoft deal
- Dianthus announces $150M common stock offering
- Dianthus price target raised to $100 from $92 at Guggenheim
- EchoStar sells spectrum licenses to SpaceX, StubHub to launch IPO: Morning Buzz
- Promising Phase II Results and Market Potential Drive Buy Rating for Dianthus Therapeutics